NasdaqGM:IRONBiotechs
How Investors Are Reacting To Disc Medicine (IRON) Balancing Larger Losses With APOLLO Phase 3 FDA Alignment
Disc Medicine, Inc. reported second-quarter 2026 results showing a net loss of US$59.53 million and basic and diluted loss per share of US$1.54, alongside progress in its bitopertin and selcodebart clinical programs.
While losses widened for the first half of 2026, alignment with the FDA on the Phase 3 APOLLO trial and positive clinical data for bitopertin and selcodebart highlight how investors may be focusing on clinical and regulatory milestones as key value drivers.
Next, we will examine...